MX2019004448A - Anticuerpos anti-virus respiratorio sincitial y metodos de generacion y uso de estos. - Google Patents
Anticuerpos anti-virus respiratorio sincitial y metodos de generacion y uso de estos.Info
- Publication number
- MX2019004448A MX2019004448A MX2019004448A MX2019004448A MX2019004448A MX 2019004448 A MX2019004448 A MX 2019004448A MX 2019004448 A MX2019004448 A MX 2019004448A MX 2019004448 A MX2019004448 A MX 2019004448A MX 2019004448 A MX2019004448 A MX 2019004448A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- generation
- antibo
- dies
- respiratory syncytial
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 241000700605 Viruses Species 0.000 title 1
- 230000003097 anti-respiratory effect Effects 0.000 title 1
- 238000002955 isolation Methods 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se proporcionan anticuerpos anti-RSV con potencia de neutralización frente RSV subtipo A y RSV subtipo B, así como los métodos para su uso identificación aislamiento generación y métodos para su preparación y uso.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662411500P | 2016-10-21 | 2016-10-21 | |
PCT/US2017/057720 WO2018075961A1 (en) | 2016-10-21 | 2017-10-20 | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019004448A true MX2019004448A (es) | 2019-08-14 |
Family
ID=60263074
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019004448A MX2019004448A (es) | 2016-10-21 | 2017-10-20 | Anticuerpos anti-virus respiratorio sincitial y metodos de generacion y uso de estos. |
Country Status (12)
Country | Link |
---|---|
US (2) | US11312761B2 (es) |
EP (1) | EP3528840A1 (es) |
JP (2) | JP2020503844A (es) |
KR (1) | KR102695416B1 (es) |
CN (1) | CN110035771B (es) |
AU (1) | AU2017345759B2 (es) |
BR (1) | BR112019008063A2 (es) |
CA (1) | CA3040886A1 (es) |
IL (3) | IL303833A (es) |
MX (1) | MX2019004448A (es) |
SG (1) | SG11201903287PA (es) |
WO (1) | WO2018075961A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018075954A2 (en) | 2016-10-21 | 2018-04-26 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
SG11201903287PA (en) | 2016-10-21 | 2019-05-30 | Adimab Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
CA3040893A1 (en) | 2016-10-21 | 2018-04-26 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
MX2021007589A (es) * | 2018-12-21 | 2021-12-10 | 23Andme Inc | Anticuerpos anti il-36 y procedimientos de uso de estos. |
US20230073132A1 (en) * | 2019-12-31 | 2023-03-09 | Medstar Health, Inc. | Anti-cd 160 binding molecules for treating diseases |
CN111172195A (zh) * | 2020-02-13 | 2020-05-19 | 翁炳焕 | 一种新冠肺炎基因治疗制品的制备方法 |
KR102467943B1 (ko) | 2020-06-25 | 2022-11-16 | 재단법인 목암생명과학연구소 | 항-rsv 항체 및 이를 포함하는 약학적 조성물 |
CN112048006B (zh) * | 2020-09-08 | 2021-04-27 | 扬州大学 | 一种替代中和效力测定的elisa方法及其应用 |
US20240034772A1 (en) * | 2020-12-08 | 2024-02-01 | Humabs Biomed Sa | Antibodies binding to f-protein of metapneumovirus and uses thereof |
JP2023554456A (ja) * | 2020-12-18 | 2023-12-27 | チューハイ トリノマブ ファーマシューティカル カンパニー リミテッド | 呼吸器合胞体ウイルスに特異的に結合する分子 |
WO2022170126A2 (en) * | 2021-02-05 | 2022-08-11 | Adagio Therapeutics, Inc. | Compounds specific to coronavirus s protein and uses thereof |
EP4393945A1 (en) * | 2021-08-25 | 2024-07-03 | Gan & Lee Pharmaceuticals Co., Ltd. | Anti-rsv antibody and application thereof |
WO2024141063A1 (zh) * | 2022-12-30 | 2024-07-04 | 甘李药业股份有限公司 | 抗rsv病毒抗体、组合物、制剂及其应用 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5824307A (en) | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
JP3976333B2 (ja) | 1992-09-16 | 2007-09-19 | ザ スクリップス リサーチ インスティチュート | 呼吸合胞体ウイルスに対するヒト中和性モノクローナル抗体 |
CA2167835A1 (en) | 1993-07-30 | 1995-02-09 | Richard A. Weltzin | Monoclonal iga antibody against respiratory syncytial virus |
US5811524A (en) | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
EP0853487B1 (en) | 1995-09-18 | 2000-07-05 | Intracel Corporation | Neutralizing monoclonal antibodies to respiratory syncytial virus |
US20020141990A1 (en) | 1996-11-01 | 2002-10-03 | Smithkline Beecham Corporation | Anti-RSV human monoclonal antibodies |
TWI310688B (en) | 1999-10-29 | 2009-06-11 | Nektar Therapeutics | Dry powder compositions having improved dispersivity |
EP1265928B1 (en) | 2000-01-27 | 2010-07-21 | Medimmune, LLC | Ultra high affinity rsv neutralizing antibodies |
US7229619B1 (en) | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
EP1259547B1 (en) | 2000-03-01 | 2012-07-11 | Medimmune, Inc. | High potency recombinant antibodies and method for producing them |
AU2001241918A1 (en) | 2000-03-02 | 2001-09-12 | Med Immune, Inc. | Methods of enhancing activity of vaccines and vaccine compositions |
ES2338098T3 (es) | 2000-05-03 | 2010-05-04 | Medimmune, Llc | Terapia de combinacion de enfermedades respiratorias usando anticuerpos y agentes antiinflamatorios. |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6855493B2 (en) | 2000-11-28 | 2005-02-15 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
US7179900B2 (en) | 2000-11-28 | 2007-02-20 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
US6818216B2 (en) | 2000-11-28 | 2004-11-16 | Medimmune, Inc. | Anti-RSV antibodies |
US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
JP4336498B2 (ja) | 2000-12-12 | 2009-09-30 | メディミューン,エルエルシー | 延長した半減期を有する分子ならびにその組成物および用途 |
US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
EP1613261A4 (en) | 2003-04-09 | 2011-01-26 | Novo Nordisk As | INTRA-CELLULAR FORMATION OF PEPTIDE CONJUGATES |
AU2004229527B2 (en) | 2003-04-11 | 2009-08-20 | Medimmune, Llc | Methods of preventing or treating respiratory conditions |
US7070786B2 (en) | 2003-06-06 | 2006-07-04 | Centocor, Inc. | RSV proteins, antibodies, compositions, methods and uses |
EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
US7700720B2 (en) | 2004-09-21 | 2010-04-20 | Medimmune, Llc | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
WO2006099481A2 (en) | 2005-03-14 | 2006-09-21 | Medimmune, Inc. | Macromolecules comprising a thioether cross-link |
PL2059532T3 (pl) | 2006-09-07 | 2013-05-31 | Crucell Holland Bv | Ludzkie cząsteczki wiążące zdolne do neutralizowania wirusa grypy H5N1 i ich zastosowania |
DE102006060799A1 (de) * | 2006-12-21 | 2008-06-26 | RUHR-UNIVERSITäT BOCHUM | RSV F-Protein und seine Verwendung |
KR20090127341A (ko) | 2007-03-06 | 2009-12-10 | 심포젠 에이/에스 | 호흡기세포 융합 바이러스 감염 치료용 재조합 항체 |
EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
WO2009030237A2 (en) | 2007-09-07 | 2009-03-12 | Symphogen A/S | Methods for recombinant manufacturing of anti-rsv antibodies |
BRPI0817257A2 (pt) | 2007-09-24 | 2015-06-16 | Univ Vanderbilt | Anticorpos moniclonais para vírus sincital respiratório e usos dos mesmos |
KR100938998B1 (ko) | 2008-01-08 | 2010-01-28 | (주) 에이프로젠 | 호흡기 신시티움 바이러스에 대한 항체 |
JP5575377B2 (ja) | 2008-07-18 | 2014-08-20 | シスメックス株式会社 | 抗rsウイルスモノクローナル抗体を用いたrsウイルス検出用キット及びイムノクロマトグラフィー用試験具、並びに新規な抗rsウイルスモノクローナル抗体 |
ES2701649T3 (es) | 2009-01-14 | 2019-02-25 | Ablynx Nv | Administración pulmonar de dominios variables individuales de inmunoglobulina y constructos de los mismos |
JP6081196B2 (ja) | 2009-06-05 | 2017-03-01 | アブリンクス エン.ヴェー. | 気道感染症の予防及び/又は治療のためのヒト呼吸器合胞体ウイルス(hRSV)に指向性を有する改良アミノ酸配列及びこれを含むポリペプチド |
BR112012003064B8 (pt) * | 2009-08-13 | 2021-05-25 | Crucell Holland Bv | anticorpo ou fragmento de ligação de antígeno do mesmo, combinação que os compreende, método de detecção de infecção por rsv, moléculas de ácido nucléico, e método de produção de um anticorpo ou fragmento de ligação de antígeno do mesmo |
US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
US20120315270A1 (en) | 2009-10-21 | 2012-12-13 | The United States Of America, As Represented By The | Rsv immunogens, antibodies and compositions thereof |
ES2778899T3 (es) | 2013-02-01 | 2020-08-12 | Medimmune Llc | Epítopos de proteína F del virus sincitial respiratorio |
TWI659968B (zh) * | 2013-03-14 | 2019-05-21 | 再生元醫藥公司 | 針對呼吸道融合病毒f蛋白質的人類抗體及其使用方法 |
EP2975052B1 (en) * | 2013-03-15 | 2020-09-23 | Xiamen University | Epitope of rsv fusion protein and antibody identifying same |
US20140323315A1 (en) | 2013-04-29 | 2014-10-30 | Adimab, Llc | Polyspecificity reagents, methods for their preparation and use |
CN104293741A (zh) * | 2014-10-10 | 2015-01-21 | 武汉大学 | 一种呼吸道合胞病毒病毒样颗粒疫苗及其制备方法和应用 |
US10713731B2 (en) | 2016-07-22 | 2020-07-14 | Nec Corporation | Method for secure ledger distribution and computer system using secure distributed ledger technology |
SG11201903287PA (en) * | 2016-10-21 | 2019-05-30 | Adimab Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
WO2018075954A2 (en) | 2016-10-21 | 2018-04-26 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
CA3040893A1 (en) | 2016-10-21 | 2018-04-26 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
-
2017
- 2017-10-20 SG SG11201903287PA patent/SG11201903287PA/en unknown
- 2017-10-20 WO PCT/US2017/057720 patent/WO2018075961A1/en unknown
- 2017-10-20 AU AU2017345759A patent/AU2017345759B2/en active Active
- 2017-10-20 IL IL303833A patent/IL303833A/en unknown
- 2017-10-20 US US16/343,297 patent/US11312761B2/en active Active
- 2017-10-20 BR BR112019008063A patent/BR112019008063A2/pt unknown
- 2017-10-20 CN CN201780074738.4A patent/CN110035771B/zh active Active
- 2017-10-20 EP EP17794546.6A patent/EP3528840A1/en active Pending
- 2017-10-20 MX MX2019004448A patent/MX2019004448A/es unknown
- 2017-10-20 JP JP2019521450A patent/JP2020503844A/ja not_active Withdrawn
- 2017-10-20 IL IL293585A patent/IL293585B2/en unknown
- 2017-10-20 KR KR1020197014483A patent/KR102695416B1/ko active IP Right Grant
- 2017-10-20 CA CA3040886A patent/CA3040886A1/en active Pending
-
2019
- 2019-04-17 IL IL266101A patent/IL266101A/en unknown
-
2021
- 2021-11-30 JP JP2021194266A patent/JP7524155B2/ja active Active
-
2022
- 2022-01-27 US US17/585,981 patent/US20220144922A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN110035771B (zh) | 2024-03-08 |
IL293585B2 (en) | 2023-11-01 |
IL293585A (en) | 2022-08-01 |
JP7524155B2 (ja) | 2024-07-29 |
US11312761B2 (en) | 2022-04-26 |
US20190256581A1 (en) | 2019-08-22 |
US20220144922A1 (en) | 2022-05-12 |
AU2017345759A1 (en) | 2019-05-23 |
JP2020503844A (ja) | 2020-02-06 |
RU2019115249A3 (es) | 2021-02-01 |
JP2022028898A (ja) | 2022-02-16 |
IL266101A (en) | 2019-06-30 |
EP3528840A1 (en) | 2019-08-28 |
CN110035771A (zh) | 2019-07-19 |
CA3040886A1 (en) | 2018-04-26 |
WO2018075961A1 (en) | 2018-04-26 |
BR112019008063A2 (pt) | 2019-07-02 |
RU2019115249A (ru) | 2020-11-24 |
IL293585B1 (en) | 2023-07-01 |
SG11201903287PA (en) | 2019-05-30 |
AU2017345759B2 (en) | 2024-06-20 |
KR20190103147A (ko) | 2019-09-04 |
IL303833A (en) | 2023-08-01 |
KR102695416B1 (ko) | 2024-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019004448A (es) | Anticuerpos anti-virus respiratorio sincitial y metodos de generacion y uso de estos. | |
WO2018075974A3 (en) | Anti-respiratory syncytial virus antibodies, and methods of their generation and use | |
EP3695003A4 (en) | ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS AND METHOD OF GENERATING AND USING THEREOF | |
JOP20200091A1 (ar) | جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري | |
CL2016002455A1 (es) | Anticuerpos multiespecíficos. | |
WO2016149710A8 (en) | Hiv-1 neutralizing antibodies and uses thereof | |
MX2021002168A (es) | Compuestos antivirales. | |
MX2017005642A (es) | Anticuerpos anti-angiopoyetina 2 (ang2) y metodos de uso. | |
MX2017003131A (es) | Metodo para la preparacion de 2-alcoxi ciclohexanol. | |
MX2017005987A (es) | Anticuerpos anti-interleucina(il)-1beta y metodos de uso. | |
PE20150945A1 (es) | Anticuerpos de antihemaglutinina y metodos de uso | |
WO2018075954A3 (en) | Anti-respiratory syncytial virus antibodies, and methods of their generation and use | |
PH12020551948A1 (en) | Monospecific and multispecific anti-tmeff2 antibodies and their uses | |
MX2017002288A (es) | Nucleosidos de 2'-cloro-aminopirimidinona y pirimidin-diona. | |
TW201612191A (en) | RSV-specific antibodies and functional parts thereof | |
MX2019010367A (es) | Formulacion acuosa de anticuerpo anti ligando 1 de muerte programada (pd-l1). | |
IN2014MU00455A (es) | ||
WO2018118754A8 (en) | Antibodies to human respiratory syncytial virus protein f pre-fusion conformation and methods of use therefor | |
WO2018093223A3 (ko) | 엘더칼시톨의 제조방법 및 그를 위한 중간체 | |
MX2019014861A (es) | Compuestos de quinolinilciclohexilpropanamida sustituidos y metodos mejorados para su preparacion. | |
DOP2017000264A (es) | Metodo para crear un compuesto a base de mercurio, compuesto a base de mercurio, metodos de uso del compuesto a base de mercurio y usos del compuesto a base de mercurio | |
AR089079A1 (es) | Formulacion de anticuerpo anti-cd44 | |
MX2017014146A (es) | Glicoproteína de hemaglutinina h7 modificada de la secuencia de influenza a/shanghai/2/2013 h7. | |
FR3025107B1 (fr) | Procede de preparation d'un antigene vaccinal, antigene vaccinal obtenu et utilisations | |
MY175821A (en) | Microorganism having ability to produce o-succinylhomoserine or succinic acid, and method for producing succinic acid or o-succinylhomoserine by using same |